Regular ArticleComparative Study of the Patients with Locally Advanced Stages I and II Cervical Cancer Treated by Radical Surgery with and without Preoperative Adjuvant Chemotherapy
References (0)
Cited by (66)
Adenocarcinoma of the uterine cervix: Pathologic features, treatment options, clinical outcome and prognostic variables
2019, Critical Reviews in Oncology/HematologyCitation Excerpt :Conversely, other investigations on patients with early stage disease who underwent primary radical hysterectomy with or without adjuvant radiotherapy or concurrent chemoradiation, reported a poorer disease-free survival [DFS] and overall survival [OS] for adenocarcinoma compared with squamous cell carcinoma (Irie et al., 2000; Nakanishi et al., 2000; Noh et al., 2014; Landoni et al., 1997; Hopkins and Morley, 1991; Park et al., 2010). Several studies on early or locally advanced cervical cancer treated with definitive radiotherapy or concurrent chemoradiation reported worse results in non squamous cell than in squamous cell carcinomas (Noh et al., 2014; Kleine et al., 1989; Oka et al., 1996; Chen et al., 1999; Katanyoo et al., 2012; Lee et al., 2015; Chen et al., 2014; Zhou et al., 2017a), and some authors found that non squamous cell carcinomas exhibited a lower response rate to neoadjuvant chemotherapy [NACT] compared with squamous cell carcinomas (Chen et al., 2008; Namkoong et al., 1995; Hwang et al., 2001). However, others authors did not confirm these observations (Cai et al., 2006; Kim et al., 2010; Xiong et al., 2011; Hu et al., 2019; Grigsby et al., 1988).
Neoadjuvant intra-arterial chemotherapy followed by total laparoscopic radical trachelectomy in stage IB1 cervical cancer
2014, Fertility and SterilityCitation Excerpt :The results of one study indicated that the diagnostic accuracy of frozen section examination of pelvic lymph nodes in patients with cervical cancer is not compromised by NACT (37). Namkoong et al. (38) reported that the tumor-free survival of patients undergoing NACT was significantly longer than patients without NACT and Chen et al. (39) reported that responders to NACT had significant lower recurrence rates and longer tumor-free survival than the responders not undergoing NACT. The advantage of NACT includes significant reduction of the size of the cervical tumor and an increase in operability of the lesion.
Neoadjuvant chemotherapy plus radical surgery followed by chemotherapy in locally advanced cervical cancer
2012, Gynecologic OncologyCitation Excerpt :However available data are very difficult to interpret. In fact the Cochrane review assembles data on both early (IB1) and locally advanced stages and it's well known that the greatest benefit of NACT is mainly seen on LACC [8,14,18,19,26,27,30,36]. Furthermore another important bias is represented by Cisplatin dosage reported in both studies, which is lower compared to that used in other studies on NACT and this may have affected the overall results.
Clinical effects of irinotecan hydrochloride in combination with cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer
2011, Gynecologic OncologyCitation Excerpt :Close attention should be given to the prevention of severe bone marrow suppression, and granulocyte clonal stimulating factor treatment may be necessary in order to ensure patient safety and the on-schedule completion of chemotherapy. In addition to reducing the size of the cervical tumor, it has been reported that patients who received NACT have less pelvic lymph node metastases, parametrial metastases and LVSI on pathological examination of surgical specimens than patients who did not receive NACT [9,10]. However some researchers provided contradicting results [11].